Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma
Public ClinicalTrials.gov record NCT00780663. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multi-Center, Open Label Study Evaluating the Efficacy and Safety of Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2, open-label, multicenter, efficacy and safety study of quarfloxin in patients with low or intermediate grade neuroendocrine cancer. The purpose of this study is to evaluate the rate of clinical benefit response to quarfloxin treatment including the reduction in secretory symptoms of flushing and/or diarrhea or the reduction quantifiable hormones or other biochemical tumor markers.
Study identification
- NCT ID
- NCT00780663
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 25 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 2008 (Type not available)
- Primary completion
- Mar 2010 (Actual)
- Completion
- Mar 2010 (Actual)
- Last update posted
- Jun 15, 2011
2008 – 2010
United States locations
- U.S. sites
- 13
- U.S. states
- 6
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Birmingham Hematology and Oncology | Birmingham | Alabama | — | — |
| Rocky Mountain Cancer Centers | Denver | Colorado | 80218 | — |
| Front Range Cancer Specialists | Fort Collins | Colorado | — | — |
| Not listed | Ocala | Florida | 34471 | — |
| Southern New Mexico Cancer Center | Las Cruces | New Mexico | — | — |
| Texas Oncology | Amarillo | Texas | — | — |
| Texas Oncology | Dallas | Texas | 75246 | — |
| El Paso Cancer Treatment Center | El Paso | Texas | — | — |
| Cancer Care Centers of South Texas | Kerrville | Texas | — | — |
| UT Health Science Center | San Antonio | Texas | 78229 | — |
| Tyler Cancer Center | Tyler | Texas | 75702 | — |
| Virginia Mason Medical Center | Seattle | Washington | 98101 | — |
| Northwest Cancer Specialists | Vancouver | Washington | 98684 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00780663, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 15, 2011 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00780663 live on ClinicalTrials.gov.